Prostate Cancer

Samir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses multiparametric MRI in prostate cancer.

Adding docetaxel to androgen-deprivation therapy improved overall survival by nearly 17 months in men with high-volume metastatic hormone-sensitive prostate cancer.

Malcolm Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses how to determine a treatment strategy for patients with prostate cancer following the 10-year PROTECT study data.

Samir Taneja, MD, discusses his research on MRI-guided prostate biopsies and other modalities in development.

Alicia Morgan, MD, Mather Hospital, discusses the impact of PARP inhibitors in prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the abiraterone acetate (Zytiga) versus docetaxel for patients with prostate cancer.

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses ongoing trials at NYU that are investigating precision oncology hypotheses.

David R. Wise, MD, PhD, discusses the promise for immunotherapy and other emerging approaches in the field of prostate cancer.

Marc A. Bjurlin, DO, discusses ongoing efforts to optimize prostate cancer screening.

Samir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses a number of emerging imaging techniques used to stage prostate cancer.

Marc A. Bjurlin, DO, clinical assistant professor, Department of Urology, NYU Langone Medical Center, discusses differentiating molecular risk assessments for patients with prostate cancer.

Malcolm Mason, MD, discusses the significance of the 10-year follow-up of the PROTECT study for patients with prostate cancer and what it means for the field going forward.

An analysis of results from 5 clinical trials showed that circulating tumor cell (CTC) conversion and CTC value ≥ 1 at baseline were superior predictors of overall survival than PSA in men with metastatic castration-resistant prostate cancer.

Alicia Morgan, MD, Mather Hospital, discusses enrolling patients with prostate cancer onto clinical trials investigating PARP inhibitors.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses treatment options for patients with newly diagnosed prostate cancer.

By combining data from genome-wide association studies with epidemiological surveys, investigators say they have developed a genetic tool that can predict age of onset for aggressive prostate cancer.

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses when to give docetaxel as a treatment option for patients with prostate cancer.

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significant results of the PROTECT study for patients with prostate cancer.

Men with newly diagnosed mCRPC in the global LATITUDE trial reported clinical improvements in pain progression, prostate cancer symptoms, fatigue, functional decline, and overallHR-QOL following treatment with abiraterone acetate plus prednisone.

Alicia Morgan, MD, Mather Hospital, discusses the role of PARP inhibitors for patients with prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the role of immunotherapy for patients with prostate cancer.

Layering of therapies and advances in next-generation imaging and sequencing are key reasons that outcomes are improving in advanced prostate cancer.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the advantages and disadvantages of choosing docetaxel as a therapy for patients with mCRPC.

For patients with oligorecurrent prostate cancer, androgen deprivation therapy–free survival was superior for those assigned to metastasis-directed therapy versus surveillance.

One-third of asymptomatic men with metastatic castration-resistant prostate cancer who progressed on enzalutamide (Xtandi) achieved a 50% decline in PSA concentration from baseline (PSA50) following bipolar androgen therapy.